$ATYR
aTyr Pharma Inc

2015 Q2 Form 10-Q Financial Statement

#000119312515227340 Filed on June 18, 2015

View on sec.gov

Income Statement

Concept 2015 Q2 2015 Q1 2014 Q1
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.400M $2.330M $1.540M
YoY Change 96.53% 51.3%
% of Gross Profit
Research & Development $7.502M $6.593M $4.388M
YoY Change 106.21% 50.25%
% of Gross Profit
Depreciation & Amortization $210.0K $209.0K $203.0K
YoY Change 0.0% 2.96%
% of Gross Profit
Operating Expenses $10.90M $8.922M $5.930M
YoY Change 103.21% 50.46%
Operating Profit -$10.90M -$8.922M -$5.930M
YoY Change 103.21% 50.46%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net -$182.0K -$149.0K -$163.0K
YoY Change -19.11% -8.59%
Pretax Income -$11.08M -$9.070M -$6.090M
YoY Change 98.21% 48.93%
Income Tax
% Of Pretax Income
Net Earnings -$11.08M -$9.071M -$6.093M
YoY Change 98.28% 48.88%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$6.556M -$5.634M -$3.783M
COMMON SHARES
Basic Shares Outstanding 23.63M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2015 Q2 2015 Q1 2014 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $103.0M $54.50M
YoY Change
Cash & Equivalents $63.07M $54.51M $24.52M
Short-Term Investments $39.90M $0.00
Other Short-Term Assets $3.200M $700.0K
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $106.2M $55.17M
YoY Change
LONG-TERM ASSETS
Property, Plant & Equipment $2.022M $1.839M
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $44.70M
YoY Change
Other Assets $146.0K $2.897M
YoY Change
Total Long-Term Assets $46.91M $4.736M
YoY Change
TOTAL ASSETS
Total Short-Term Assets $106.2M $55.17M
Total Long-Term Assets $46.91M $4.736M
Total Assets $153.1M $59.91M
YoY Change
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.002M $3.168M
YoY Change
Accrued Expenses $2.817M $2.645M
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $3.200M $5.200M
YoY Change
Total Short-Term Liabilities $9.372M $11.55M
YoY Change
LONG-TERM LIABILITIES
Long-Term Debt $3.500M $4.300M
YoY Change
Other Long-Term Liabilities $588.0K $380.0K
YoY Change
Total Long-Term Liabilities $588.0K $380.0K
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $9.372M $11.55M
Total Long-Term Liabilities $588.0K $380.0K
Total Liabilities $9.960M $11.93M
YoY Change
SHAREHOLDERS EQUITY
Retained Earnings -$130.3M -$119.2M
YoY Change
Common Stock $269.7M $21.22M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $139.3M -$98.01M
YoY Change
Total Liabilities & Shareholders Equity $153.1M $59.91M
YoY Change

Cashflow Statement

Concept 2015 Q2 2015 Q1 2014 Q1
OPERATING ACTIVITIES
Net Income -$11.08M -$9.071M -$6.093M
YoY Change 98.28% 48.88%
Depreciation, Depletion And Amortization $210.0K $209.0K $203.0K
YoY Change 0.0% 2.96%
Cash From Operating Activities -$11.21M -$6.290M -$6.350M
YoY Change 128.78% -0.94%
INVESTING ACTIVITIES
Capital Expenditures -$40.00K $123.0K $211.0K
YoY Change 0.0% -41.71%
Acquisitions
YoY Change
Other Investing Activities -$84.92M $1.950M -$5.400M
YoY Change -136.11%
Cash From Investing Activities -$84.97M $1.830M -$5.610M
YoY Change 212325.0% -132.62%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $69.00K $13.00K
YoY Change 430.77%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 104.7M 45.07M 10.00K
YoY Change 1969.76% 450600.0%
NET CHANGE
Cash From Operating Activities -11.21M -6.290M -6.350M
Cash From Investing Activities -84.97M 1.830M -5.610M
Cash From Financing Activities 104.7M 45.07M 10.00K
Net Change In Cash 8.550M 40.61M -11.95M
YoY Change 7025.0% -439.83%
FREE CASH FLOW
Cash From Operating Activities -$11.21M -$6.290M -$6.350M
Capital Expenditures -$40.00K $123.0K $211.0K
Free Cash Flow -$11.17M -$6.413M -$6.561M
YoY Change 129.84% -2.26%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
36457000
CY2014Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
73487415 shares
CY2014Q4 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.001
CY2014Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
95500000 shares
CY2014Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
909880 shares
CY2014Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2014Q1 us-gaap Share Based Compensation
ShareBasedCompensation
146000
CY2014Q4 us-gaap Temporary Equity Liquidation Preference
TemporaryEquityLiquidationPreference
95619000
CY2014Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
295000
CY2014Q4 us-gaap Loans Payable Current
LoansPayableCurrent
3134000
CY2014Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
95619000
CY2014Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
445000
CY2014Q4 us-gaap Interest Payable Current And Noncurrent
InterestPayableCurrentAndNoncurrent
500000
CY2014Q4 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
2000000
CY2014Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1433000
CY2014Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2932000
CY2014Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-110151000
CY2014Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
20644000
CY2014Q4 us-gaap Common Stock Value
CommonStockValue
1000
CY2014Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
75772871 shares
CY2014Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
11053954 shares
CY2014Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
909880 shares
CY2014Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
73487415 shares
CY2014Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
19209000
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
-91010000
CY2014Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
335000
CY2014Q4 us-gaap Long Term Loans From Bank
LongTermLoansFromBank
5142000
CY2014Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2014Q4 us-gaap Liabilities Current
LiabilitiesCurrent
10113000
CY2014Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
319000
CY2014Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2210000
CY2014Q4 us-gaap Assets
Assets
20644000
CY2014Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1925000
CY2014Q4 us-gaap Receivable From Shareholders Or Affiliates For Issuance Of Capital Stock
ReceivableFromShareholdersOrAffiliatesForIssuanceOfCapitalStock
69000
CY2014Q4 us-gaap Assets Current
AssetsCurrent
16509000
CY2014Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
1954000
CY2014Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
656000
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
13899000
CY2015Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
23634531 shares
CY2014Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
24517000
CY2015Q1 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
141654309 shares
CY2015Q1 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.001
CY2015Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
185000000 shares
CY2015Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1029731 shares
CY2015Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2015Q1 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
143939765 shares
CY2015Q1 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
21064955 shares
CY2015Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1029731 shares
CY2015Q1 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
141654309 shares
CY2015Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
21215000
CY2015Q1 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
1287000
CY2015Q1 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
610000
CY2015Q1 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
369000
CY2015Q1 us-gaap Interest Payable Current And Noncurrent
InterestPayableCurrentAndNoncurrent
500000
CY2015Q1 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
2000000
CY2015Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
3168000
CY2015Q1 us-gaap Stockholders Equity
StockholdersEquity
-98006000
CY2015Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
380000
CY2015Q1 us-gaap Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
446000
CY2015Q1 us-gaap Long Term Loans From Bank
LongTermLoansFromBank
4322000
CY2015Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2645000
CY2015Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-119222000
CY2015Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
59905000
CY2015Q1 us-gaap Common Stock Value
CommonStockValue
1000
CY2015Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2015Q1 us-gaap Liabilities Current
LiabilitiesCurrent
11545000
CY2015Q1 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
242000
CY2015Q1 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
231000
CY2015Q1 us-gaap Temporary Equity Liquidation Preference
TemporaryEquityLiquidationPreference
171898000
CY2015Q1 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
300000
CY2015Q1 us-gaap Loans Payable Current
LoansPayableCurrent
3190000
CY2015Q1 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
141295000
CY2015Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2897000
CY2015Q1 us-gaap Other Assets Miscellaneous Noncurrent
OtherAssetsMiscellaneousNoncurrent
200000
CY2015Q1 us-gaap Assets
Assets
59905000
CY2015Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1839000
CY2015Q1 us-gaap Assets Current
AssetsCurrent
55169000
CY2015Q1 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
0
CY2015Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
657000
CY2015Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
54512000
CY2015Q1 life Number Of Variable Interest Entities
NumberOfVariableInterestEntities
6 Entity
CY2011Q4 life Lease Agreement Extended Term
LeaseAgreementExtendedTerm
P5Y
CY2014Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-6345000
CY2014Q1 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
67878 shares
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0214 pure
CY2014Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-7.87
CY2014Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
10484507 shares
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.111 pure
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000 pure
CY2014Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
791283 shares
CY2014Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
211000
CY2014Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
5397000
CY2014Q1 us-gaap Net Income Loss
NetIncomeLoss
-6093000
CY2014Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-6231000
CY2014Q1 us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
138000
CY2014Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
30000
CY2014Q1 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
100000
CY2014Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-94000
CY2014Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-5930000
CY2014Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-163000
CY2014Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-3000
CY2014Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
203000
CY2014Q1 life Increase Decrease In Deferred Rent Credit
IncreaseDecreaseInDeferredRentCredit
-66000
CY2015Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2014Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-11940000
CY2014Q1 us-gaap Operating Expenses
OperatingExpenses
5930000
CY2014Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-5608000
CY2014Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
13000
CY2014Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4388000
CY2014Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
13000
CY2014Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-732000
CY2014Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
146000
CY2015Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-6286000
CY2014Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1542000
CY2014Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
70000
CY2015Q1 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
39439 shares
CY2015Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2015
CY2015Q1 dei Amendment Flag
AmendmentFlag
false
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0153 pure
CY2015Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-9.39
CY2015Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
19728684 shares
CY2015Q1 dei Document Type
DocumentType
10-Q
CY2015Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001339970
CY2015Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2015Q1 us-gaap Debt Instrument Maturity Date
DebtInstrumentMaturityDate
2015-05-13
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.009 pure
CY2015Q1 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
On May 5, 2015, the Company filed an amendment to its amended and restated certificate of incorporation to effect a one-for-7.95413 reverse stock split of the Company's common stock (the Reverse Stock Split). The par value and the authorized shares of the common and convertible preferred stock were not adjusted as a result of the Reverse Stock Split.
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000 pure
CY2015Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2015Q1 dei Entity Registrant Name
EntityRegistrantName
ATYR PHARMA INC
CY2015Q1 dei Document Period End Date
DocumentPeriodEndDate
2015-03-31
CY2015Q1 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
7.95413 pure
CY2015Q1 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>Use of Estimates</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> The Company&#x2019;s consolidated financial statements are prepared in accordance with GAAP. The preparation of the Company&#x2019;s consolidated financial statements requires it to make estimates and assumptions that impact the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in the Company&#x2019;s consolidated financial statements and accompanying notes. The most significant estimates in the Company&#x2019;s consolidated financial statements relate to the fair value of equity issuances and awards, and clinical trials and research and development expense accruals. Although these estimates are based on the Company&#x2019;s knowledge of current events and actions it may undertake in the future, actual results may ultimately differ materially from these estimates and assumptions.</p> </div>
CY2015Q1 dei Trading Symbol
TradingSymbol
LIFE
CY2015Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
966322 shares
CY2015Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
123000
CY2015Q1 us-gaap Net Income Loss
NetIncomeLoss
-9071000
CY2015Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-9071000
CY2015Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
187000
CY2015Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
501000
CY2015Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-8922000
CY2015Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-149000
CY2015Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-4000
CY2015Q1 us-gaap Repayments Of Bank Debt
RepaymentsOfBankDebt
795000
CY2015Q1 us-gaap Share Based Compensation
ShareBasedCompensation
603000
CY2015Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-77000
CY2015Q1 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
100000
CY2015Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
40613000
CY2015Q1 us-gaap Operating Expenses
OperatingExpenses
8922000
CY2015Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
1827000
CY2015Q1 us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
46299000
CY2015Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
45072000
CY2015Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6593000
CY2015Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
69000
CY2015Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
765000
CY2015Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
603000
CY2015Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2329000
CY2015Q1 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
1411000
CY2015Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
128000
CY2015Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
1950000
CY2015Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
209000
CY2015Q1 life Noncancellable Operating Leases Term Of Expiration
NoncancellableOperatingLeasesTermOfExpiration
2017-05
CY2015Q1 life Deferred Offering Costs In Accounts Payable And Accrued Liabilities
DeferredOfferingCostsInAccountsPayableAndAccruedLiabilities
1233000
CY2015Q1 life Increase Decrease In Deferred Rent Credit
IncreaseDecreaseInDeferredRentCredit
-71000

Files In Submission

Name View Source Status
0001193125-15-227340-index-headers.html Edgar Link pending
0001193125-15-227340-index.html Edgar Link pending
0001193125-15-227340.txt Edgar Link pending
0001193125-15-227340-xbrl.zip Edgar Link pending
d933897d10q.htm Edgar Link pending
d933897dex141.htm Edgar Link pending
d933897dex311.htm Edgar Link pending
d933897dex312.htm Edgar Link pending
d933897dex321.htm Edgar Link pending
d933897dex322.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
life-20150331.xml Edgar Link completed
life-20150331.xsd Edgar Link pending
life-20150331_cal.xml Edgar Link unprocessable
life-20150331_def.xml Edgar Link unprocessable
life-20150331_lab.xml Edgar Link unprocessable
life-20150331_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending